|
Mechanism5-HT2A receptor antagonists [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia
This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.
100 Clinical Results associated with Cyrenaic Pharmaceuticals, Inc.
0 Patents (Medical) associated with Cyrenaic Pharmaceuticals, Inc.
100 Deals associated with Cyrenaic Pharmaceuticals, Inc.
100 Translational Medicine associated with Cyrenaic Pharmaceuticals, Inc.